Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 42
Filter
2.
Rev Med Interne ; 41(1): 46-49, 2020 Jan.
Article in French | MEDLINE | ID: mdl-31735371

ABSTRACT

INTRODUCTION: Myalgia is a classical sign in invasive meningococcal diseases (IMD), but severe and persistent myalgia following an IMD have never been reported to date. CASE REPORT: A 20-year-old man presented with purpura fulminans and meningitis caused by Neisseria meningitidis serogroup Y, revealing properdin deficiency. Although meningitis symptoms improved after antibiotherapy, initial myalgia of the lower limbs increased, associated with mild rhabdomyolysis. Magnetic resonance imaging (MRI) revealed an increased STIR (Short TI inversion recovery) signal of both quadriceps muscles, without abscess. After exclusion of other causes of myopathy, a post-infectious myositis was diagnosed. A four-week course of corticosteroids led to dramatic improvement. CONCLUSION: Post-infectious inflammatory myopathy should be suspected in case of severe and persistent myalgia associated with rhabdomyolysis following an IMD, after exclusion of pyomyositis especially. A short course of corticosteroids seems to be effective.


Subject(s)
Meningitis, Meningococcal/complications , Myalgia/microbiology , Myositis/microbiology , Properdin/deficiency , Rhabdomyolysis/microbiology , Humans , Male , Neisseria meningitidis , Purpura Fulminans/complications , Young Adult
3.
Rev Epidemiol Sante Publique ; 67(3): 149-154, 2019 May.
Article in English | MEDLINE | ID: mdl-30833042

ABSTRACT

BACKGROUND: In France, the most severe bone and joint infections (BJI), called "complex" (CBJI), are assessed in a multidisciplinary team meeting (MTM) in a reference center. However, the definition of CBJI, drawn up by the Health Ministry, is not consensual between physicians. The objective was to estimate the agreement for CBJI classification. METHODS: Initially, five experts from one MTM classified twice, one-month apart, 24 cases as non-BJI, simple BJI or CBJI, using the complete medical record. Secondly, six MTMs classified the same cases using standardized information. Agreements were estimated using Fleiss and Cohen kappa (κ) coefficients. RESULTS: Inter-expert agreement during one MTM was moderate (κ=0.49), and fair (κ=0.23) when the four non-BJIs were excluded. Intra-expert agreement was moderate (κ=0.50, range 0.27-0.90), not improved with experience. The overall inter-MTM agreement was moderate (κ=0.58), it was better between MTMs with professor (κ=0.65) than without (κ=0.51) and with longer median time per case (κ=0.60) than shorter (κ=0.47). When the four non-BJIs were excluded, the overall agreement decreased (κ=0.40). CONCLUSION: The first step confirmed the heterogeneity of CBJI classification between experts. The seemingly better inter-MTM than inter-expert agreement could be an argument in favour of MTMs, which are moreover a privileged place to enhance expertise. Further studies are needed to assess these results as well as the quality of care and medico-economic outcomes after a MTM.


Subject(s)
Arthritis, Infectious/therapy , Bone Diseases, Infectious/therapy , Interdisciplinary Communication , Patient Care Team/organization & administration , Adult , Aged , Arthritis, Infectious/epidemiology , Bone Diseases, Infectious/epidemiology , Cooperative Behavior , Female , France/epidemiology , Group Processes , Humans , Male , Middle Aged , Patient Care Team/standards
4.
Ann Dermatol Venereol ; 143(12): 841-845, 2016 Dec.
Article in French | MEDLINE | ID: mdl-27742137

ABSTRACT

BACKGROUND: Visceral leishmaniasis is not normally expressed in skin. Herein, we describe the case of an HIV-positive patient who developed two unusual skin manifestations during an episode of visceral leishmaniasis. PATIENTS AND METHODS: A 48-year-old female patient consulted initially for infiltrated purpura of all four limbs. Skin biopsy revealed leukocytoclastic vasculitis with Leishman-Donovan bodies. Laboratory tests showed medullary, splenic, gastric and colic involvement, suggesting systemic disease, and enabling visceral leishmaniasis to be diagnosed. Two years later, despite prolonged treatment, the patient presented maculopapular exanthema, and histology revealed persistent Leishman-Donovan bodies. DISCUSSION: We report herein an association of two rare skin manifestations in an HIV-positive patient with visceral leishmaniasis: infiltrated purpura and maculopapular exanthema. However, the underlying mechanisms remain hypothetical. The initial leukocytoclastic exanthema could be secondary to either polyclonal hypergammaglobulinaemia or to IgA deposits, or possibly to mechanical impairment of blood vessels by the actual parasite. The maculopapular exanthema occurring later raised the possibility of post-Kala-Azar leishmaniasis due to blood-borne dissemination in an anergic subject or perhaps even immune reconstitution inflammatory syndrome.


Subject(s)
Exanthema/etiology , HIV Infections/complications , Leishmaniasis, Visceral/diagnosis , Purpura/etiology , Biopsy , Female , Humans , Leishmaniasis, Visceral/complications , Middle Aged , Skin/pathology
6.
Med Mal Infect ; 45(6): 207-14, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25982343

ABSTRACT

BACKGROUND: The 2010-2014 HIV/AIDS French program recommends using HIV rapid diagnostic tests in family practice. Our aim was to assess the acceptability and feasibility of the RDT in family practice in France. METHODS: The first part of this study was to determine the opinions of family practitioners (FPs) concerning the news guidelines for screening and the possible use of rapid HIV tests in their practice. The second part was a feasibility study of the actual use of rapid HIV tests given to FPs during six months. The third part was a qualitative analysis of experience feedback to determine the impediments to using rapid HIV tests. RESULTS: Seventy-seven percent of the 352 FPs interviewed were favorable to rapid HIV tests use. The three main impediments were: misinterpretation of test result, complexity of quality control, and lack of training: 23 of the 112 FPs having volunteered to evaluate the rapid HIV tests followed the required training session. Sixty-nine tests were handed out, and three rapid HIV tests were used; the qualitative study involved 12 FPs. The participants all agreed on the difficult use of rapid HIV tests in daily practice. The main reasons were: too few opportunities or requests for use, complex handling, difficulties in proposing the test, fear of having to announce seropositivity, significantly longer consultation. CONCLUSION: Although FPs are generally favorable to rapid HIV tests use in daily practice, the feasibility and contribution of rapid HIV tests are limited in family practice.


Subject(s)
AIDS Serodiagnosis/methods , Family Practice/methods , HIV Infections/diagnosis , Physicians, Family/psychology , AIDS Serodiagnosis/statistics & numerical data , Adult , Attitude of Health Personnel , Feasibility Studies , Female , France/epidemiology , HIV Antibodies/blood , HIV Infections/epidemiology , HIV-1/immunology , HIV-2/immunology , Humans , Male , Middle Aged , Patient Acceptance of Health Care , Physician-Patient Relations , Practice Patterns, Physicians' , Prospective Studies , Quality Assurance, Health Care , Sampling Studies , Sensitivity and Specificity , Surveys and Questionnaires , Time Factors
9.
Med Mal Infect ; 44(7): 292-301, 2014 Jul.
Article in English | MEDLINE | ID: mdl-25011930

ABSTRACT

UNLABELLED: Rabies is responsible for 50,000 deaths per year worldwide. Mainland France has been officially freed from rabies in non-flying animals since 2001. METHOD: We wanted to provide an update on the French situation, using published data, and describe possible options since official guidelines are lacking. RESULTS: Post-exposure prophylaxis (PEP) (early and careful cleaning and dressing of the wound, vaccination, and in case of high-risk exposure, injection of specific anti-rabies immunoglobulins) is known to be efficient except in rare cases. It is recommended after grade II contact (+specific immunoglobulins in immunodepressed patients), or grade III contact (vaccination+immunoglobulins). DISCUSSION: Mainland France being rabies-free, 3 options may be considered in case of bite by a dog or a cat that cannot be monitored in France: (a) consider the risk of rabies as null, so no PEP should be administrated, whatever the severity of bites; (b) consider there is a weak but lethal risk, so the international recommendations should be applied, using immunoglobulins in some cases; (c) consider that the risk is extremely low but cannot be excluded, and that the patient should be vaccinated to be protected, but without adding immunoglobulins (whether in case of grade II or III bites). CONCLUSION: There are no national guidelines for rabies in France, and so the physician managing the patient is the one who will decide to treat or not.


Subject(s)
Post-Exposure Prophylaxis/methods , Rabies/epidemiology , Administration, Oral , Animals , Animals, Wild/virology , Antibodies, Viral/administration & dosage , Antibodies, Viral/therapeutic use , Bites and Stings/therapy , Bites and Stings/virology , Chiroptera/virology , Disease Reservoirs , Dogs , Foxes , France/epidemiology , French Guiana/epidemiology , Global Health , Humans , Immunization, Passive , Lyssavirus/genetics , Lyssavirus/pathogenicity , Malpractice , Pets/virology , Post-Exposure Prophylaxis/standards , Practice Guidelines as Topic , Rabies/prevention & control , Rabies/transmission , Rabies/veterinary , Rabies/virology , Rabies Vaccines/therapeutic use , Rabies virus/genetics , Rabies virus/immunology , Rhabdoviridae Infections/epidemiology , Rhabdoviridae Infections/veterinary , Rhabdoviridae Infections/virology , Risk , Travel , Vaccination/methods , Vaccination/veterinary , World Health Organization , Zoonoses
12.
Med Mal Infect ; 42(9): 421-8, 2012 Sep.
Article in English | MEDLINE | ID: mdl-22938775

ABSTRACT

OBJECTIVE: The authors had for aim to describe the effectiveness and the safety of a saquinavir/ritonavir (SQV/r) regimen, 1000/100mg twice daily, in HIV-infected pregnant patients. PATIENTS AND METHOD: We made a prospective and observational study of HIV positive female patients beginning or going on SQV/r antiretroviral treatment (ART) during pregnancy. RESULTS: Sixty-two patients were enrolled from July 2007 to June 2009 in 10 infectious diseases units in France. Thirty-six women (group 1) were ART naive on inclusion, 20 (group 2) had been previously treated and then switched to SQV/r, six (group 3) were treated with SQV/r before pregnancy. 58 patients delivered while on SQV/r regimen after a median pregnancy duration of 39 WA. Eighty percent had a viral load below 50 copies/mL and 93% below 400 copies/mL: respectively 77% and 93.5% in group 1, 83% and 89% in group 2, 83% and 100% in group 3. The median SQV minimum concentrations (C(min)) measured at the third trimester and at delivery were adequate, respectively 0.91 mg/L and 0.86 mg/L. Most women (52%) had a vaginal delivery; 12 (21%) had an elective caesarean section, for obstetrics factors in eight cases. None of the newborns were HIV-infected at 6 months of age (n = 59, one death at day 3). Only one severe adverse event occurred due to saquinavir (maternal grade 3 hepatotoxicity). CONCLUSION: SQV/r 1000/100mg twice daily seems to be effective and safe in HIV-infected pregnant women with adequate saquinavir C(min).


Subject(s)
HIV Infections/drug therapy , HIV Protease Inhibitors/therapeutic use , HIV-1 , HIV-2 , Pregnancy Complications, Infectious/drug therapy , Ritonavir/therapeutic use , Saquinavir/therapeutic use , Adult , CD4 Lymphocyte Count , Chemical and Drug Induced Liver Injury/etiology , Cohort Studies , Delivery, Obstetric/statistics & numerical data , Drug Therapy, Combination , Female , HIV Infections/congenital , HIV Infections/prevention & control , HIV Infections/transmission , HIV Protease Inhibitors/administration & dosage , HIV Protease Inhibitors/adverse effects , Humans , Infant, Newborn , Infectious Disease Transmission, Vertical/prevention & control , Male , Pregnancy , Pregnancy Outcome , Prospective Studies , Ritonavir/administration & dosage , Ritonavir/adverse effects , Saquinavir/administration & dosage , Saquinavir/adverse effects , Treatment Outcome , Viral Load , Viremia/drug therapy , Young Adult , Zidovudine/administration & dosage , Zidovudine/therapeutic use
13.
Eur J Clin Microbiol Infect Dis ; 31(7): 1413-8, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22037775

ABSTRACT

US and European guidelines recommend a daily divided gentamicin dose (3 mg/kg in two or three equally divided doses) for the treatment of infective endocarditis caused by staphylococci or enterococci, but once-daily dosing (3 mg/kg/day) is recommended for streptococcal endocarditis. However, studies have recommended the use of higher doses of gentamicin (4 or ≥5 mg/kg/day) administered once-daily. A survey was conducted in France by mailing a questionnaire to the 595 members of the French Infectious Disease Society regarding their gentamicin prescription patterns in infective endocarditis, focusing on the dosing regimen. The survey was answered by 137 physicians (23%). The proportions of physicians following guideline-based regimens were similar for each organism (30.9%, 38.8%, and 39.4% for staphylococci, enterococci, and streptococci, respectively [p=0.26]). In contrast, the proportions of physicians following literature-based regimens were significantly different for each organism (59.6%, 42.5%, and 27.7% for staphylococci, enterococci, and streptococci, respectively [p<0.001]). The number of years practicing and the type of practice (university vs. non-university hospital) did not influence the gentamicin dose or regimen. Although adherence to published guidelines for gentamicin administration in patients with infective endocarditis was poor, a large proportion of physicians who did not follow those guidelines used literature-based regimens.


Subject(s)
Anti-Bacterial Agents/administration & dosage , Endocarditis/drug therapy , Gentamicins/administration & dosage , Gram-Positive Bacterial Infections/drug therapy , Guideline Adherence/statistics & numerical data , Prescriptions/statistics & numerical data , Drug Therapy/methods , Endocarditis/microbiology , France , Gram-Positive Bacterial Infections/microbiology , Humans , Physicians , Surveys and Questionnaires
14.
Eur J Clin Microbiol Infect Dis ; 27(8): 671-8, 2008 Aug.
Article in English | MEDLINE | ID: mdl-18357478

ABSTRACT

Bacteraemia due to anaerobic bacteria occurs infrequently, making the systematic use of an anaerobic blood sample bottle in patients with sepsis controversial. We retrospectively reviewed the clinical and microbiological data from all cases of anaerobic bacteraemia in a teaching hospital over 2 years and determined the prognostic factors and antibiotic management. With the goal of evaluating the morbidity and mortality of bacteraemia due to anaerobic bacteria, a case-control study was also performed. One hundred eighty-four blood cultures from 125 patients grew at least one anaerobic bacterium, representing 0.5% of all and 7.0% of the positive blood cultures. One hundred seventeen patients were studied. In 24 cases, anaerobic blood cultures were associated with concomitant aerobic bacteria isolation. The most frequently isolated anaerobic species were Bacteroides sp. (n = 62), Clostridium sp. (n = 25), and Fusobacterium sp. (n = 12). The most frequent site of origin was the digestive tract (n = 61). In 51 cases, patients did not receive adequate empirical antianaerobic therapy. The mortality rate was 27%. Age [odds ratio (OR) 1.059; 95% confidence interval (CI) 1.021-1.100], cancer history (OR 3.21, 95% CI 1.126-9.156), and ineffective definitive antibiotherapy (OR 19.292, 95% CI 5.330-69.832) were independently associated with increased hospital mortality. The 72 patients that could be matched with patients without anaerobic bacteria according to their primary diagnosis had a longer hospitalisation and a trend toward increased mortality (P = 0.08). Anaerobic bacteraemia contributed significantly to the morbidity of the patients, and adequate empirical antibiotherapy may play an important role in the clinical outcomes.


Subject(s)
Bacteremia/therapy , Bacteria, Anaerobic , Anti-Bacterial Agents/therapeutic use , Bacteremia/epidemiology , Bacteremia/microbiology , Bacteria, Anaerobic/drug effects , Case-Control Studies , Cross Infection , Humans , Risk Factors , Treatment Outcome
15.
Semin Arthritis Rheum ; 36(5): 269-77, 2007 Apr.
Article in English | MEDLINE | ID: mdl-17207522

ABSTRACT

OBJECTIVES: To compare the risk of relapse of vertebral osteomyelitis (VO), according to the duration of antibiotic therapy (< or =6 weeks versus >6 weeks). METHODS: We performed a 10-year retrospective study to assess the risk of VO relapse and to verify that this risk was not enhanced in patients who received 6 weeks of antibiotic therapy (Group 1) as compared with those who received a longer treatment (Group 2). VO was diagnosed based on clinical manifestations, magnetic resonance imaging and/or computed tomography findings, and isolation of a pyogenic organism in blood cultures and/or a discovertebral biopsy. Relapse was diagnosed based on isolation of the same organism in blood cultures and/or a discovertebral biopsy. Outcome was evaluated 6 months post-treatment and in December 2004. RESULTS: Group 1 included 36 patients (mean age, 58 +/- 15 years) and Group 2 included 84 patients (mean age, 67 +/- 15 years) (P = 0.003). Clinical data and microorganisms were comparable in the 2 groups. In the first 6 months, 6 (5%) patients died (Group 1, n = 2; Group 2, n = 4), and 5 (4%) in Group 2 relapsed, 2 with recurrent VO and 3 with recurrent bacteremia. In 2004, 91 patients were evaluated (mean follow-up, 40.6 +/- 31 months): 77 (85%) were cured, 13 (14%) died (Group 1, n = 3; Group 2, n = 10), 1 had VO due to a different microorganism (Group 2), and no long-term relapses occurred. CONCLUSION: Our results suggest that antibiotic therapy of VO could be safely shortened to 6 weeks without enhancing the risk of relapse.


Subject(s)
Anti-Bacterial Agents/administration & dosage , Osteomyelitis/drug therapy , Spinal Diseases/drug therapy , Adolescent , Adult , Aged , Aged, 80 and over , Drug Administration Schedule , Drug Therapy, Combination , Female , Humans , Male , Middle Aged , Osteomyelitis/pathology , Osteomyelitis/prevention & control , Recurrence , Retrospective Studies , Spinal Diseases/microbiology , Spinal Diseases/pathology , Time Factors , Treatment Outcome
16.
Med Mal Infect ; 37(2): 108-11, 2007 Feb.
Article in French | MEDLINE | ID: mdl-17254729

ABSTRACT

OBJECTIVES: Imogam rage (IgR) prescriptions were assessed in the rabies prophylaxis centre of Poitiers (France). MATERIAL AND METHODS: All medical records closed between January 1 and June 1, 2005 were retrospectively analyzed. An infectious disease specialist examined the pertinence of IgR prescription according to WHO references adapted to the epidemiological situation by the Pasteur Institute French rabies center. The indicator used was the proportion of patients treated by IgR among all patients treated by vaccination or vaccination with IgR. RESULTS: During the study period, 69 medical records have bewereen analyzed: 48 (70%) patients were treated including 22 (46%) with IgR. Imogam rage indication was not appropriate for 21 (95%) patients (one contact with a rodent, 8 low gravity contact, 12 contacts with a French animal) that is to say 86 IgR vials. The direct cost was 8,032 euros. CONCLUSION: This assessment permitted to underline an overprescription of IgR, to adapt guidelines to the local situation, and to improve care quality by adaptating medical record files, improving the prescription decisional tree and the local guidelines, and improving the training of interns.


Subject(s)
Immunotherapy, Active , Rabies Vaccines/therapeutic use , Rabies/prevention & control , Algorithms , Animals , Animals, Domestic , Animals, Wild , Bites and Stings/therapy , Case Management , Chiroptera , Drug Costs , Drug Prescriptions/statistics & numerical data , Drug Utilization , Environmental Exposure , France , Health Facilities/statistics & numerical data , Humans , Immunotherapy, Active/economics , Immunotherapy, Active/statistics & numerical data , Rabies/transmission , Rabies Vaccines/economics , Rodentia , Unnecessary Procedures
17.
Eur J Radiol ; 61(1): 150-3, 2007 Jan.
Article in English | MEDLINE | ID: mdl-16987630

ABSTRACT

OBJECTIVE: Legionella pneumonia is usually classified as "atypical pneumonia", which suggests a predominance of interstitial patterns in chest X-rays. Based on a selection of recent clinical cases and a brief review of the literature, the aim of the study is to clarify, how far the actual radiological findings would be consistent with these expectations. PATIENTS AND METHODS: A retrospective analysis of 18 epidemic personal cases and a review of the literature data were performed to describe the chest X-ray findings of Legionella pneumophila (LP) community acquired pneumonia. X-ray review was performed simultaneously and in consensus by two radiologists (J.P.T., E.C.) and a physician (C.G.). RESULTS: From our series, 17 patients had an abnormal chest X-ray on admission. Among these pathological X-ray cases, infiltrates were more often confluent (n=16), or patchy (n=7), rather than interstitial (n=1). Fifteen patients had infiltrates involving the lower lung fields. Bilateral distribution of abnormalities and pleural effusion were each observed in three cases. Radiological findings deteriorated between the second and seventh days following admission, particularly in the form of patchy infiltrates with pleural effusion. The review of the literature is consistent with these findings, by reporting prevalent confluent or patchy infiltrates. CONCLUSIONS: These findings are consistent with the physiopathological particularity of this affection and incite us to avoid the classification "atypical pneumonia" in radiologic terminology. This term is more appropriate for clinical and microbiological use.


Subject(s)
Legionnaires' Disease/classification , Legionnaires' Disease/diagnostic imaging , Lung Diseases, Interstitial/classification , Lung Diseases, Interstitial/diagnostic imaging , Pneumonia/classification , Pneumonia/diagnostic imaging , Terminology as Topic , Female , France , Humans , Lung/diagnostic imaging , Male , Middle Aged , Radiography
18.
Eur J Clin Microbiol Infect Dis ; 25(11): 715-7, 2006 Nov.
Article in English | MEDLINE | ID: mdl-17033788

ABSTRACT

Mycoplasma hominis has been associated with pelvic inflammatory illness, postpartum and neonatal infections and respiratory tract diseases. It is rarely isolated from patients with other infections. Reported here is a case of tibial osteitis that occurred in a 16-year-old immunocompetent man. Clinical and laboratory findings improved under treatment with clindamycin and fluoroquinolones.


Subject(s)
Mycoplasma Infections/microbiology , Mycoplasma hominis/isolation & purification , Osteitis/microbiology , Tibia/microbiology , Adolescent , Humans , Immunocompetence , Male , Mycoplasma hominis/classification , Mycoplasma hominis/genetics
19.
Clin Infect Dis ; 43(5): e51-2, 2006 Sep 01.
Article in English | MEDLINE | ID: mdl-16886143

ABSTRACT

We describe 2 cases of mild botulism in patients who inhaled cocaine. Botulism, though rare, is increasing in incidence among illicit drug users. To our knowledge, these are the first cases of botulism in illicit drug users in France. Clinicians should be aware of this phenomenon; botulism should be considered in illicit drug users with neurological symptoms.


Subject(s)
Botulism/etiology , Cocaine-Related Disorders/complications , Administration, Inhalation , Adult , Botulism/epidemiology , Drug Contamination , France/epidemiology , Humans , Male
20.
J Infect ; 51(2): E5-9, 2005 Aug.
Article in English | MEDLINE | ID: mdl-16038751

ABSTRACT

We describe three cases of Fusobacterium spp. diskitis and review with attention to risk factors, clinical features, diagnosis, treatment and outcome. In most of the reported cases, a ear-nose-throat infection was found. Clinical manifestations were similar to those of classic bacterial vertebral osteomyelitis. Clindamycin is the most appropriate antibiotic. The outcome seems to be very good without relapse with appropriate treatment compared to pyogenic vertebral osteomyelitis.


Subject(s)
Fusobacterium Infections/diagnosis , Fusobacterium necrophorum , Fusobacterium nucleatum , Osteomyelitis/diagnosis , Spinal Diseases/diagnosis , Aged , Anti-Bacterial Agents/administration & dosage , Clindamycin/administration & dosage , Discitis/diagnosis , Discitis/drug therapy , Discitis/microbiology , Drug Therapy, Combination , Female , Fusobacterium Infections/drug therapy , Fusobacterium Infections/microbiology , Fusobacterium necrophorum/isolation & purification , Fusobacterium nucleatum/isolation & purification , Humans , Lumbar Vertebrae , Male , Middle Aged , Osteomyelitis/drug therapy , Osteomyelitis/microbiology , Penicillins/administration & dosage , Spinal Diseases/drug therapy , Spinal Diseases/microbiology , Thoracic Vertebrae , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...